StockData

NuCana plc (NCNA) stock

NCNANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 19, 2026Score 1/30
$0.83−0.06 (-6.42%)

Close on Nov 18, 2026Market cap $3.47MP/E –Yield –

NuCana operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

NuCana's operating income for the twelve months ending Dec 31, 2021 was -£47.91M. For fiscal 2025 it was -£20.11M. The highest annual figure on record is -£6.91M in fiscal 2015.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-£20.11M–
FY2024Dec 31, 2024-£22.81M–
FY2023Dec 31, 2023-£32.78M–
FY2022Dec 31, 2022-£39.12M–
FY2021Dec 31, 2021-£47.91M–
FY2020Dec 31, 2020-£36.42M–
FY2019Dec 31, 2019-£26.70M–
FY2018Dec 31, 2018-£19.13M–
FY2017Dec 31, 2017-£25.69M–
FY2016Dec 31, 2016-£8.45M–
FY2015Dec 31, 2015-£6.91M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-£3.55M–
Q2 FY2025Jun 30, 2025-£11.83M–
Q2 FY2024Jun 30, 2024-£8.35M–
Q2 FY2023Jun 30, 2023-£6.28M–
Q2 FY2022Jun 30, 2022-£5.22M–
Q4 FY2021Dec 31, 2021-£15.74M–
Q3 FY2021Sep 30, 2021-£9.97M–
Q2 FY2021Jun 30, 2021-£10.71M–
Q1 FY2021Mar 31, 2021-£11.49M–
Q4 FY2020Dec 31, 2020-£13.97M–
Q3 FY2020Sep 30, 2020-£9.62M–
Q2 FY2020Jun 30, 2020-£7.41M–
Q1 FY2020Mar 31, 2020-£5.42M–
Q4 FY2019Dec 31, 2019-£9.11M–
Q3 FY2019Sep 30, 2019-£5.04M–
Q2 FY2019Jun 30, 2019-£5.88M–
Q1 FY2019Mar 31, 2019-£6.68M–
Q4 FY2018Dec 31, 2018-£5.10M–
Q3 FY2018Sep 30, 2018-£3.58M–
Q2 FY2018Jun 30, 2018-£2.95M–
Q1 FY2018Mar 31, 2018-£7.49M–
Q4 FY2017Dec 31, 2017-£5.87M–
Q3 FY2017Sep 30, 2017-£14.27M–
Q2 FY2017Jun 30, 2017-£3.54M–

More NuCana figures

See a number that looks wrong?